Phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIGA) is the catalytic core of the GPI-GnT complex, initiating the first step of glycosylphosphatidylinositol (GPI) anchor biosynthesis in the endoplasmic reticulum. Somatic mutations in the X-linked PIGA gene lead to Paroxysmal Nocturnal Hemoglobinuria (PNH), while germline mutations cause severe neurodevelopmental disorders (MCAHS2). As gene therapies, mRNA-based restoratives, and small-molecule modulators targeting the GPI-anchor pathway advance, robust in vitro and cell-based assay systems are critical to validate therapeutic efficacy and off-target safety.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PIGA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PIGA Recombinant Protein (Partial/Soluble Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View PIGA Products |
| Gene Delivery | PIGA Lentivirus Premade Particles Full-length human PIGA ORF for stable cell line generation and rescue assays. |
View PIGA Products |
| Benchmark Ab | Anti-PIGA Recombinant Control Antibody Sequence-verified high-affinity positive control for ELISA/WB. |
View PIGA Products |
| Validator | PIGA siRNA Set For targeted knockdown verification in GPI-anchor deficiency modeling. |
View PIGA Products |
| Related Target A | CD59 GPI-anchored complement regulator; primary surface marker for PIGA functional readouts. |
View CD59 Products |
| Related Target B | CD55 (DAF) Complement decay-accelerating factor; co-marker with CD59 to assess GPI-anchor integrity. |
View CD55 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass ER membrane protein expression | Lentivirus-mediated stable cell line construction to maintain native ER topology and enzymatic conformation. |
| Quantifying GPI-anchor biosynthesis rescue | Co-screening assays featuring sequence-verified CD59 and CD55 recombinant proteins for flow cytometry standards. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated positive controls. |
| False Positives in Knockdown | Multi-target siRNA pool to ensure highly specific PIGA gene silencing. |
Live PIGA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the PIGA pathway is entering a pivotal phase. While traditional management of PNH relies heavily on downstream terminal complement inhibitors (C5 inhibitors like eculizumab), curative efforts are shifting toward restoring upstream PIGA function. The next wave of R&D focuses on mRNA-based lipid nanoparticles (LNPs) and AAV-delivered gene therapies designed to re-establish GPI-anchor synthesis in hematopoietic stem cells or neural tissues, alongside the development of small-molecule inhibitors targeting the GPI pathway for specialized oncological or antifungal applications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / LNP-mRNA | Academic Institutes, Biotech Startups | PIGA Deficiency, MCAHS2, PNH | Functional Rescue Assay (Need PIGA Lentivirus for stable expression & CD55/CD59 flow readout) |
| Small Molecule Inhibitors | Pharma / Antifungal Developers | Fungal Infections, Select Solid Tumors | Enzymatic Inhibition Screening (Need High-Purity Recombinant PIGA fragments) |
| RNA Interference (siRNA) | Functional Genomics Labs | Disease Modeling (PNH phenocopy) | Targeted Knockdown Validation (Need Sequence-Verified PIGA siRNA) |